BioAge Labs Files 8-K on Financial Results & Reg FD Disclosure

TL;DR

**BioAge Labs just dropped an 8-K with financial results, check EX-99.1 for the numbers!**

AI Summary

BioAge Labs, Inc. filed an 8-K on March 24, 2026, reporting on its results of operations and financial condition under Item 2.02, and making Regulation FD disclosures under Item 7.01. This filing includes an exhibit (EX-99.1) which likely contains the detailed financial information. Investors should pay close attention to the specific financial results in EX-99.1 to understand the company's recent performance and future outlook, as this directly impacts the stock's valuation.

Why It Matters

This filing provides crucial updates on BioAge Labs' financial health and operational performance, which are key indicators for current and prospective investors to assess the company's value and future potential.

Risk Assessment

Risk Level: medium — The risk level is medium because while the filing itself is routine, the actual financial results contained within EX-99.1 could significantly impact the stock price, either positively or negatively.

Analyst Insight

A smart investor would immediately review Exhibit 99.1 of this 8-K to understand the specific financial results and operational conditions reported by BioAge Labs, as these details will drive market reaction.

Key Players & Entities

• BioAge Labs, Inc. (company) — the filer of the 8-K
• 0001709941 (company) — CIK of BioAge Labs, Inc.
• 2026-03-24 (date) — filing date and period of report
• 5885 HOLLIS STREET SUITE 370 EMERYVILLE CA 94608 (company) — mailing and business address of BioAge Labs, Inc.

FAQ

Key Financial Figures

• $0.00001 — nge on which registered Common Stock, $0.00001 Par Value Per Share BIOA Nasdaq Glo

Filing Documents

• bioa-20260324.htm (8-K) — 50KB
• bioa-ex99_1.htm (EX-99.1) — 237KB
• img161644396_0.gif (GRAPHIC) — 4KB
• 0001193125-26-120864.txt ( ) — 415KB
• bioa-20260324.xsd (EX-101.SCH) — 25KB
• bioa-20260324_htm.xml (XML) — 5KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On March 24, 2026, BioAge Labs, Inc. (the " Company ") issued a press release announcing its financial results for the year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure The Company has also updated its corporate deck, which is available in the "Investors" portion of the Company's website at https://ir.bioagelabs.com/. The information in Item 2.02 and this Item 7.01, including Exhibit 99.1 attached to this report, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the " Securities Act "). The information contained in Item 2.02, this Item 7.01, and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by BioAge Labs, Inc. dated March 24, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOAGE LABS, INC. Date: March 24, 2026 By: /s/ Dov Goldstein Dov Goldstein, M.D. Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR